Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
about
Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolutionComprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3ACYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropionA mechanistic view of polybrominated diphenyl ether (PBDE) developmental neurotoxicityConformational Adaptation of Human Cytochrome P450 2B6 and Rabbit Cytochrome P450 2B4 Revealed upon Binding Multiple Amlodipine MoleculesStructures of Cytochrome P450 2B6 Bound to 4-Benzylpyridine and 4-(4-Nitrobenzyl)pyridine: Insight into Inhibitor Binding and Rearrangement of Active Site Side ChainsInvestigation by site-directed mutagenesis of the role of cytochrome P450 2B4 non-active-site residues in protein-ligand interactions based on crystal structures of the ligand-bound enzymeInsights into CYP2B6-mediated drug-drug interactionsInfluence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patientsCYP2B6 gene single nucleotide polymorphisms and leukemia susceptibilityGlutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with CyclophosphamideCYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with CyclophosphamideStructural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs.Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylationCopy variations in schizophrenia and bipolar disorder.Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.Metabolism of profenofos to 4-bromo-2-chlorophenol, a specific and sensitive exposure biomarker.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations.Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.CYP2B6*6 is associated with increased breast cancer risk.CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeAnandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase cStructural and biophysical characterization of human cytochromes P450 2B6 and 2A6 bound to volatile hydrocarbons: analysis and comparison.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.Chiral polychlorinated biphenyls: absorption, metabolism and excretion--a reviewCYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native peopleWorldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.Effect of pregnancy on the disposition of 2,2',3,5',6-pentachlorobiphenyl (PCB 95) atropisomers and their hydroxylated metabolites in female miceDirect inhibition of Re Du Ning Injection and its active compounds on human liver cytochrome P450 enzymes by a cocktail method.Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers.Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping indexRapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavirPharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance
P2860
Q24294558-1B85B699-AFC4-40FD-BEEF-A2ED3BE909FFQ24317436-45B1E591-C662-4862-B5A8-CF25DECE8DEEQ24634660-553ACA50-8BFF-4B1F-B9A4-DF63065F65EEQ26853456-9845B267-E999-4BCD-813D-33EC35F0BBB9Q27671627-29BD2AD7-BDD6-4EB2-923B-5F1826CD8815Q27672416-4F7190A5-0C38-423F-99FC-477D064B1350Q27675363-01AD225D-7192-4A3F-A23E-41C1FBB5F6D5Q28078857-99D0D6AD-BD09-47A4-B0BD-F417A215EC4BQ28293875-3EEBC47A-DE4A-4F1D-A12B-4CEA0C979A8EQ28294323-6EB5453E-BD5F-483D-8E71-0C2AB3669C3BQ28550922-332C2F42-3CFD-4FFD-8B62-0D739FFF4261Q28552450-A388CBC5-D991-4BE5-AC1D-B4353474BADAQ30396630-1F7F7538-E536-40AC-B8EF-6A43187FCE0AQ33640426-AE69BF04-D72F-4CEF-A000-356BCF3CA41FQ34015667-34D3BF82-2049-4544-A17E-3432EC13FB62Q34060410-BC27F74B-1A33-41EB-AA5E-08B7F67CD4FDQ34165511-C2CC566E-7BBC-447D-8C95-3FD6AD40B78CQ34328153-5D0EF824-E9BA-466C-A2A4-CEFCB69E1C0CQ34443184-DE5AF5A5-BE15-4C76-A7FC-F05CDC4FFA96Q34457423-51F328C0-D33E-460A-9577-EBC66403295BQ34491448-2397470E-2424-4B83-BA19-45784C94FAB3Q34737523-97D51AFD-7879-4A24-8B56-099005900499Q34793437-9AE74B0C-AF37-4F5E-9352-5DF6FD743B45Q34824471-35CCADF5-DDB5-4022-8F46-3F2D9AEC24AFQ34856974-3063CB14-5EB4-4805-872D-9D5209FF8765Q34975110-EEBAEB44-FD21-48DA-9111-200294706A80Q35188159-3B6B37BF-60D3-4B96-A9CE-F2C3CC8C2F65Q35198035-D28946A2-DA53-40D9-AB04-4F814BA04236Q35518558-CF20F787-5D36-4D07-AAB4-86B66EB19CD7Q35547723-8DD7C3DB-94F6-4698-9527-4A9D3083C59CQ35846912-B0666307-34E8-4042-BE4F-A99937AA4338Q35925302-85DB17CD-5FF9-46F9-9FAE-CB1B474655A1Q35949266-2D58BFDA-A715-450F-B617-B8083701341AQ36079108-A3800AFE-FE70-4F7C-B72B-491DDE41F4D5Q36083543-7AE85595-4D31-4889-A1D0-19E3C492E79FQ36205082-4A55B594-6F72-4324-B8D5-3BE3AA47F1DAQ36406247-47C432B8-BE71-486B-8CB5-34C20F6B1A0EQ36562516-00875A7C-ED20-47E7-8E97-7D8116730A25Q36593838-4A3778ED-8A93-449A-AF9D-137EEBA7E5B9Q36657589-BCB20D33-8F6B-40FE-802F-3CBCAA41DD4C
P2860
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
@en
type
label
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
@en
prefLabel
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
@en
P2093
P2860
P356
P1433
P1476
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
@en
P2093
Julia Blievernicht
Kathrin Klein
Marco H Hofmann
Matthias Schwab
Tanja Saussele
P2860
P304
P356
10.2217/14622416.8.7.743
P577
2007-07-01T00:00:00Z